Biophytis Modifies Financing Agreement with Hexagon Capital Fund

On May 27, 2026, Biophytis announced changes to its financing agreement with Hexagon Capital Fund. The modifications, finalized on May 22, 2026, aim to improve the company's financial structure by establishing a renewable €2 million facility and reducing borrowing costs. This strategic move aligns with Biophytis’ goal of ensuring sufficient resources for its clinical developments.

The financing agreement now features a revolving credit facility. This allows Biophytis to reissue up to 2,000 bonds upon repayment, providing enhanced financial agility. Additionally, the annual interest rate on these bonds has been lowered from 12% to 10%, reflecting Hexagon's confidence in Biophytis' strategic plans.

Biophytis is preparing to launch a joint venture in Hong Kong, marking the initiation of its Phase 3 sarcopenia study. The financial adjustments will support this venture and upcoming programs in obesity, enhancing Biophytis' capacity to achieve its clinical milestones.